Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An 8-week, Randomized, Phase 2, Double-blind, Sequential Parallel-group Comparison Study Of Two Dose Levels Of Pf 06372865 Compared To Placebo As An Adjunctive Treatment In Outpatients With Inadequate Response To Standard Of Care For Generalized Anxiety Disorder

NCT02310568 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT02310568
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02310568 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An 8-week, Randomized, Phase 2, Double-blind, Sequential Parallel-group Comparison Study Of Two Dose Levels Of Pf 06372865 Compared To Placebo As An Adjunctive Treatment In Outpatients With Inadequate Response To Standard Of Care For Generalized Anxiety Disorder
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Terminated
Start date
November 30, 2014
Completion date
October 31, 2015
Enrollment
90 (actual)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

generalized anxiety disorder